









Applicants: Arlindo L. Castelhana et al.
 Serial No.: Not Yet Known
 Filed : Herewith
 Page 2

Amendments to the Specification



















On page 1, after the title, please insert the following paragraph:

-- This application is a divisional of U.S. Application No. 09/728,229, filed December 1, 2000, now allowed, which is a continuation of PCT International Application No. PCT/US99/12135, filed June 1, 1999, designating the United States of America, which is a continuation-in-part and claims priority of U.S. Provisional Application No. 60/087,702, filed June 2, 1998, U.S. Provisional Application No. 60/123,216, filed March 8, 1999 and U.S. Provisional Application No. 60/126,527, filed March 26, 1999 the contents of which are hereby incorporated by reference. --

Please replace the portions of Table 1 appearing on pages 42-43, with the following:


R	M ⁺ + H	R	M ⁺ + H
	343.2		351.27
	343.18		430.35
	337.21		359.44
	364.19		404.32

Applicants: Arlindo L. Castelhana et al.
 Serial No.: Not Yet Known
 Filed : Herewith
 Page 3


	330.18		330.45
	347.22		339.47
	350.28		353.41
	344.19		324.45
	394.16		359.38
	371.12		379.40
	359.39		387.41
	403.33		344.48
	351.49		337.53

Applicants: Arlindo L. Castelhana et al.
Serial No.: Not Yet Known
Filed : Herewith
Page 4

On page 85, please insert the following scheme before the paragraph beginning on line 24:



On page 87, please insert the following structure above the number "25" appearing on line 10:



Applicants: Arlindo L. Castelhana et al.
Serial No.: Not Yet Known
Filed : Herewith
Page 5

Please amend the paragraph beginning on page 94, line 25 as follows:

-- The genetic markers are as described in ~~Example 1~~ above, except for the G-protein variation. For human A_{2a} receptor-expression, yeast strains were utilized in which the endogenous yeast G protein GPA1 had been deleted and replaced by a mammalian G_{αs}. Three rat G_{αs} mutants were utilized. These variants contain one or two point mutations which convert them into proteins which couple efficiently to yeast βγ. They are identified as G_{αs}E10K (in which the glutamic acid at position ten is replaced with lysine), G_{αs}D229S (in which the aspartic acid at position 229 is replaced with serine) and G_{αs}E10K+D229S (which contains both point mutations). --

Please amend the paragraph appearing on page 98, lines 25-30 as follows:

-- In order to determine if this inhibitory effect was specific to the A₁ subtype, a series of complementary experiments were performed with the yeast-based A_{2a} receptor assay ~~(described in Example 4)~~. Results obtained with the A_{2a} yeast-based assay indicated that XAC was a relatively effective A_{2a} receptor antagonist, consistent with published reports. In contrast, DPCPX was relatively inert at this receptor, as expected from published reports.--


Please amend the paragraph appearing on page 103, lines 1-4 as follows:

-- For a further description of the assays identified, see U.S. Application ~~Serial No. 09/088985~~, Publication No. US-2002-0015967-A1, published February 7, 2002, entitled "Functional Expression of Adenosine Receptors in Yeast", ~~filed June 2, 1998~~

Applicants: Arlindo L. Castelhana et al.
Serial No.: Not Yet Known
Filed : Herewith
Page 6

now abandoned, the entire contents of which are hereby incorporated herein by reference. --


On page 124, please insert the following structure below the line which states "Profile of Selective A2b Antagonists":



Please amend the abstract of the invention appearing on page 158, lines 4-5 as follows:

~~-- Novel deazapurines are disclosed which are useful for the treatment of adenosine stimulated diseases.~~

This invention pertains to compounds having the structure:



wherein R₁ and R₂ together form a substituted or unsubstituted heterocyclic ring; R₃ is a substituted or unsubstituted aryl moiety; R₄ is a hydrogen atom, an unsubstituted alkyl, or a substituted or unsubstituted aryl moiety; and R₅ and R₆ are each independently a halogen atom, a hydrogen atom or a substituted or unsubstituted alkyl, aryl, or alkylaryl moiety, or a

Applicants: Arlindo L. Castelhana et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 7

pharmaceutically acceptable salt thereof, and the use of these compounds to treat a disease associated with increased levels of adenosine in a subject. --